Allogene Therapeutics, INC Form 4 insider transactions

Douglas Earl Martin, SVP, General Counsel of Allogene Therapeutics, Inc., reports selling 6,404 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Geoffrey M. Parker, CFO of Allogene Therapeutics, sold 4,361 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Timothy L. Moore, Chief Technical Officer of Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Allogene Therapeutics CEO David Chang sold 46,003 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Zachary Roberts, EVP of R&D at Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Allogene Therapeutics' SVP, General Counsel, Earl Douglas Martin, acquired 144,928 shares and 512,370 stock options on January 24, 2025.

Allogene Therapeutics' Chief Financial Officer, Geoffrey M. Parker, acquired shares and stock options on January 24, 2025.

Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, acquired 36,232 shares and was granted options for 128,093 shares on January 24, 2025.

Allogene Therapeutics EVP of R&D, Zachary Roberts, acquired 173,913 shares and 614,844 stock options on January 24, 2025.

Director Arie Belldegrun of Allogene Therapeutics reports acquiring shares and stock options, while also disclosing indirect holdings through various entities.

Allogene Therapeutics CEO David Chang acquired shares and stock options, as well as reporting existing holdings, in a recent SEC filing.

Zachary Roberts, EVP of R&D at Allogene Therapeutics, sold 27,199 shares of common stock on January 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Deborah M. Messemer, an executive at Allogene Therapeutics, sold shares in multiple transactions at a weighted average price of $2.18.

Director Franz B. Humer of Allogene Therapeutics sold 9,221 shares of common stock at an average price of $2.16 per share on December 5, 2024.

Geoffrey M. Parker, CFO of Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Douglas Earl Martin, SVP, General Counsel of Allogene Therapeutics, sold 28,310 shares of common stock on August 21, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Deborah Messemer sold 18,641 shares of Allogene Therapeutics (ALLO) common stock at a weighted average price of $2.2793 per share on June 18, 2024, under a pre-arranged 10b5-1 trading plan.

Director Stephen Mayo acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Director Elizabeth Barrett acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Director Vicki Sato reports acquiring and disposing of Allogene Therapeutics shares and stock options on June 5, 2024.

Director Franz B. Humer reports acquisition of Allogene Therapeutics shares and stock options.

Director Owen N. Witte acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Director Joshua A. Kazam acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Director Deborah M. Messemer reports acquiring and disposing of Allogene Therapeutics (ALLO) common stock on June 5, 2024.

Director Franz B. Humer sold 11,200 shares of Allogene Therapeutics, Inc. at an average price of $2.3376 on May 30, 2024.

Director Arie Belldegrun reports acquisition of Allogene Therapeutics shares through direct purchase and entities he is associated with.

Allogene Therapeutics' CFO, Geoffrey M. Parker, acquired 344,828 shares of common stock in a registered direct offering on May 16, 2024.

Allogene Therapeutics CEO David Chang acquired 344,828 shares of common stock through a registered direct offering at a price of $2.9 per share.

Timothy L. Moore, Chief Technical Officer of Allogene Therapeutics, sold 17,360 shares of common stock on April 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Allogene Therapeutics CEO David Chang sold shares to cover tax withholding obligations related to vesting restricted stock units, as mandated by the company's equity incentive plan.